EasyNAT Rapid Flu Assay
Ongoing Challanges
Rapid antigen tests have low sensitivity (30-70%), especially late in the illness, often leading to false-negative diagnoses. RT-PCR is more accurate but not universally available.
Influenza (flu), a highly contagious respiratory illness, causes severe outcomes in the elderly, young children, pregnant women, and immunocompromised individuals.
The WHO estimates 290,000–650,000 annual deaths globally. High morbidity and mortality lead to increased healthcare costs, lost productivity, and strain on hospitals during peak seasons.
Product Overview
The EasyNAT Rapid Flu Assay is an automated nucleic acid test for the qualitative detection of Influenza A/B virus RNA in throat swabs from symptomatic patients with relevant epidemiological risk factors.
Accurate test results in 25 minutes
Accurate LOD: 400 copies/mL
The highly automated operation does not require a three-zone PCR lab, making it suitable for all levels of healthcare institutions.
Clinical Value
Differentiates between Flu A and Flu B, enabling targeted treatment.
Sensitive PCR testing contributes to early identification, preventing widespread transmission during the respiratory season.
Reduces turn-around time, avoids secondary visits, and improves the patient experience.
